Concise Analysis of Biologics and Biosimilars World Markets - Tucson News Now

Concise Analysis of Biologics and Biosimilars World Markets

  • HealthMore>>

  • FDA to propose e-cigarette regulations

    FDA to propose e-cigarette regulations

    © FDA© FDA
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.
    The U.S. Food and Drug Administration is proposing long-awaited regulations governing the fast-growing electronic cigarette industry.
  • People seek out health info when famous person dies

    People seek out health info when famous person dies

    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...
    WEDNESDAY, April 23, 2014 (HealthDay News) -- The deaths of well-known people offer an opportunity to educate the general public about disease detection and prevention, a new study suggests. Researchers surveyed 1,400 American men and women after Apple co-founder Steve Jobs died of pancreatic cancer in 2011 and learned that more than one-third of them sought information about his cause of death or information about cancer in general soon after his death was reported. About 7 percent of th...
  • 1 in 13 U.S. schoolkids takes psych meds

    1 in 13 U.S. schoolkids takes psych meds

    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.
    More than 7 percent of American schoolchildren are taking at least one medication for emotional or behavioral difficulties, a new government report shows.

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Research and Markets

DUBLIN, February 5, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/9lglrg/biologics_and) has announced the addition of the "Biologics and Biosimilars World Markets" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


Biologics are complex molecules manufactured through cell culture recombinant DNA technology. Biologics additionally comprise recombinant insulin, growth hormone and monoclonal antibodies for treating conditions such as cancer and autoimmunity. Also known as follow-on biologics or subsequent entry biologics (SEBs), biosimilars are to biologics what generics are to branded drugs; they lower healthcare expenditures. This report anticipates that the global biologic drugs market will jump to over $220 billion by 2019.

The study describes the emergence of biologics and biosimilars and their potential role in shaping the future of the global healthcare industry. The study analyzes the changing dynamics of the pharmaceutical market and provides insight into the regulatory pathways for branded pharmaceuticals and biologics, patent expirations, business strategies, clinical trials and drug applications.

Biologics, also known as biopharmaceuticals, can be categorized into three main modalities: therapeutic proteins, monoclonal antibodies and vaccines. Most of the biologic drugs marketed so far are recombinant therapeutic protein drugs, which are used to relieve patients suffering from chronic diseases, such as cancer, diabetes, cardiovascular diseases, infertility and cystic fibrosis. Globally, the U.S. commands 43% of biologics sales, followed by the E.U. (21%) and Japan (9%).

Key biologics and biosimilars are covered by the report, including Humira (Adalimumab), Remicade (Infliximab), Lantus (Insulin Glargine), Levemir (Insulin Detemir), Privigen (Immune Globulin Intravenous), Aranesp (Darbepoetin Alfa), Enbrel (Etanercept), Herceptin (Trastuzumab) and Remicade (Infliximab). Moreover, this report examines companies that are actively developing and marketing biologics and biosimilars in the world. Detailed tables and charts with sales forecasts and marketshare data are also included.


Key Topics Covered: 

1. Overview

2. Pharmaceutical Industry: An Overview

3. Brand Name Pharmaceuticals: A Brief Overview

4. Generic Drugs: A Brief Overview

5. Biologics

6. Biosimilars

7. Company Profiles


Companies Mentioned:

  • AbbVie, Inc
  • Abbott Laboratories
  • Actelion Ltd
  • Amgen, Inc
  • Amoytop Biotech Co, Ltd
  • Anhui Anke Biotechnology (Group) Co, Ltd
  • Apotex, Inc
  • Astellas Pharma, Inc
  • AstraZeneca
  • Bayer AG
  • Beijing Four Rings Biopharmaceuticals
  • Bharat Serums and Vaccines Limited
  • Bio, Inc
  • Biocon Ltd
  • Biogen Idec, Inc
  • Bioton SA
  • Boehringer Ingelheim Pharmaceuticals, Inc
  • Bristol-Myers Squibb, Co
  • Celgene Corporation
  • Celltrion, Inc
  • Cipla Ltd
  • Dr Reddy's Laboratories Ltd
  • Elan Corporation, PLC
  • Eli Lilly & Co
  • Gideon Richter
  • Gilead Sciences, Inc
  • GlaxoSmithKline PLC
  • Hospira, Inc
  • Intas Pharmaceuticals Limited
  • Johnson & Johnson
  • Merck & Co, Inc
  • Mylan, Inc
  • Novartis AG
  • Pfizer, Inc
  • Roche Holdings AG
  • Sandoz International GmbH
  • Sanofi
  • Stada Arzneimittel Aktiengesellschaft
  • Teva Pharmaceutical Industries Limited
  • Watson Pharmaceuticals, Inc


For more information visit http://www.researchandmarkets.com/research/9lglrg/biologics_and


Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net


©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow